Autologous bone marrow-derived mononuclear cells for treatment of acute ischemic stroke

This trial aims to assess safety, feasibility and efficacy of intravenously delivered autologous bone marrow mononuclear (mainly CD34+) cells in patients with acute ischemic stroke. The study attempted to determine dose-response gradients of stem cell therapy and to explore risk-to-benefit ratios for autologous stem cell therapy in these patients.